Okuvision

Name

Okuvision

Legal name

Okuvision GmbH

Website

https://okuvision.de

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

Keywords

• Transcorneal electrical stimulation
• Retinal disease therapy
• Ophthalmic medical devices
• Retinitis pigmentosa treatment
• Neurostimulation devices

Headquarters

HQ city

Reutlingen

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. OkuStim® 2 Neurostimulator Device Sales: Sale of the programmable neurostimulator device to patients via clinical competence centers. The device is assembled in-house from components and sold with CE marking under EU MDR.
2. OkuEl® M Electrode Consumables: Ongoing revenue from single-use silver-coated electrode filaments. Patients perform weekly therapy requiring electrode consumables on a recurring basis.
3. Health Insurance Reimbursement (Pending): G-BA trial study ongoing (results expected 2027) to establish long-term efficacy. Upon positive assessment, statutory health insurance reimbursement is expected, which would significantly expand market access in Germany.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Okuvision manufactures the OkuStim system, comprising the OkuStim 2 programmable neurostimulator and OkuEl M single-use silver-coated electrodes, for transcorneal electrical stimulation (TES) therapy. The device delivers weak electrical impulses via the cornea to activate neuroprotective mechanisms in the retina, slowing the progression of visual field loss in patients with degenerative retinal diseases such as retinitis pigmentosa.

Product overview

Okuvision offers a medical device therapy platform centered on the OkuStim® system for transcorneal electrical stimulation (TES) of the retina. The product portfolio includes the original OkuStim® system and its successor OkuStim® 2 (CE marked December 2025), both comprising a programmable neurostimulator and ultra-thin silver-coated OkuEl® M electrodes. The therapy delivers weak electrical impulses through the cornea to stimulate retinal cells, activating neuroprotective mechanisms that slow disease progression in Retinitis pigmentosa and potentially other degenerative retinal conditions. Treatment is self-administered at home once weekly for 30 minutes after clinical instruction. Okuvision also conducts and supports multiple clinical studies including the G-BA Trial Study and TES-GAP study for geographic atrophy.

Differentiator

Problem solved

Functional benefit

Brands

• OkuStim®: Transcorneal electrical stimulation (TES) therapy system for treatment of Retinitis pigmentosa
• OkuStim® 2
• OkuEl® M

Products and services

• OkuStim 2 Neurostimulator Programmable neurostimulator device for transcorneal electrical stimulation (TES) therapy to slow visual field loss in patients with Retinitis pigmentosa. CE marked under EU MDR, designed for independent home use once weekly for 30 minutes, with individually adjustable current intensity safely below one milliampere and software-supported patient workflows.
• OkuStim System (Original) First-generation transcorneal electrical stimulation system consisting of a neurostimulator device and electrodes. Delivers weak electrical impulses through the cornea to stimulate retinal cells, activating neuroprotective mechanisms that slow Retinitis pigmentosa progression. Used as a home-based therapy performed once weekly for 30 minutes.
• OkuEl M Electrodes Ultra-thin, silver-coated single-use electrode filaments placed directly on the lower eyelid for transcorneal electrical stimulation. Consumable component of the OkuStim 2 system required for each weekly therapy session, manufactured in-house to high cleanliness and quality standards.

Quantifiable outcome

• Slows visual field loss progression in RP patients in a dose-dependent manner (Stett et al., TVST 2023;12:29)
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core.

• PRO RETINA Deutschland e.V.coreStrategic or Co-development PartnerLongstanding partnership with PRO RETINA, a major German patient organization for retinal diseases. Collaboration on patient education, awareness, and support. PRO RETINA's EUTB counseling center provides free participation counseling including for OkuStim cost reimbursement.
• Retina SuissecoreStrategic or Co-development PartnerSwiss patient organization partner working together on patient education and awareness for RP patients in Switzerland, where Okuvision has many users.
• Retina InternationalcoreStrategic or Co-development PartnerInternational umbrella organization of patient associations for retinal diseases. Partnership strengthens global patient outreach and awareness.
• University Eye Clinic TübingencoreImplementation/ SI/ Consulting PartnerCentral research and clinical partner. Site of the first TES studies (EST 1, EST 2), ongoing studies, and where CEO Dr. Alfred Stett began his retinal implant research in 1996. Also a TES-GAP study center.
• Retina Implant AG (Founder)coreStrategic or Co-development PartnerFounded in 2007 by Retina Implant AG, which was developing an implantable electronic chip for blind patients. Okuvision emerged from Retina Implant's decision to also develop a neuroprotective therapy without retinal implant.
• Klinikum Stuttgart – KatharinenhospitalcoreImplementation/ SI/ Consulting PartnerTES-GAP study center for geographic atrophy evaluation. One of five German clinical sites recruiting 70 patients for the multizentrische Pilotstudie.
• Universitätsklinikum UlmcoreImplementation/ SI/ Consulting PartnerTES-GAP study center for geographic atrophy evaluation.
• LMU Klinikum MünchencoreImplementation/ SI/ Consulting PartnerTES-GAP study center for geographic atrophy evaluation.
• UKE HamburgcoreImplementation/ SI/ Consulting PartnerTES-GAP study center for geographic atrophy evaluation.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• GenSight Biologics: Clinical-stage gene therapy company developing treatments for Leber Hereditary Optic Neuropathy and Retinitis Pigmentosa. Addresses the same patient population as OkuStim via a competing one-time curative modality rather than chronic electrical stimulation.
• SparingVision: Gene therapy company focused on RP and glaucoma with lead asset SPVN06 entering pivotal trials. Competes directly for the same RP patients through a disease-modifying rather than neuroprotective approach.
• jCyte: Cell therapy company developing jCell, a retinal progenitor cell therapy for RP, targeting the same patient population with a one-time intravitreal injection alternative to chronic neurostimulation.
• ProQR Therapeutics: RNA-editing therapeutics company developing antisense oligonucleotides for inherited retinal diseases including RP (Usher syndrome type 2A). Competes for the same rare ophthalmology patient population through a modality that targets underlying genetic cause.
• Pixium Vision: French retinal implant company developing the PRIMA bionic vision system for atrophic dry AMD and RP-related vision loss. Competes for end-stage RP patients with a photovoltaic subretinal prosthesis instead of transcorneal stimulation.

Emerging players

• Second Sight Medical Products (now Cortigent / Cirle): Company developing the Orion cortical visual prosthesis and successor to the Argus II retinal implant for blindness. Targets the same end-stage RP population with an implanted electrode array rather than non-invasive TES.
• Nano Retina: Israeli company developing the NR600 artificial retina, a bio-retina implant for patients with degenerative retinal diseases. Competes for advanced RP patients via a miniaturized retinal prosthetic rather than electrical neurostimulation.

Broad incumbents

• Medtronic: Global leader in implantable neurostimulation devices (spinal cord, deep brain, vagus nerve stimulation). Shares the underlying electrical neurostimulation technology platform with OkuStim but applies it to non-ophthalmic indications at far larger scale.
• Carl Zeiss Meditec: Large diversified ophthalmic medical technology company offering diagnostic, surgical, and laser devices to ophthalmologists globally. Serves the same clinical customers in the same practices where OkuStim is fitted, though without a direct neurostimulation product.

Others

• Heidelberg Engineering: Specialized ophthalmic imaging and diagnostics company (Heidelberg Retina Tomograph, Spectralis OCT) used extensively in RP and AMD clinical workup. Serves the same ophthalmology clinical customer base as OkuStim but supplies diagnostic rather than therapeutic equipment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/okuvision-gmbh
• Instagraminstagram.com/okuvision
• Facebookfacebook.com/okuvision
• Xx.com/okuvision_

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Okuvision